CellaVision AB (publ) (LON: 0MR5)

Market Cap	373.58M
Revenue (ttm)	54.23M
Net Income (ttm)	11.05M
Shares Out	n/a
EPS (ttm)	0.46
PE Ratio	33.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	May 6, 2024

Volume	37
Average Volume	369
Open	222.75
Previous Close	224.50
Day's Range	226.50 - 226.50
52-Week Range	13.40 - 21.16
Beta	1.23
RSI	44.78
Earnings Date	Feb 6, 2025

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers ...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1994
• Employees: 228
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MR5

Financial Performance

In 2023, CellaVision AB's revenue was 677.29 million, an increase of 5.94% compared to the previous year's 639.34 million. Earnings were 130.31 million, an increase of 10.12%.

Financial numbers in SEK